Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 plus gemcitabine versus gemcitabine in second-line advanced pancreatic adenocarcinoma after FOLFIRINOX failure
2018-000377-68Phase 3Completed
- Sponsor
- SynCore Biotechnology
- Start
- Apr 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing EndoTAG-1 plus gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started Apr 2018; status: completed.
02
Drugs
EndoTAG-1gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-000377-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000377-68.